MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Enables Consumers to Own, Manage, Sell Data via BIGtoken Platform

SRAX (NASDAQ: SRAX), a digital-marketing and consumer-data-management technology platform company, provides a secure and transparent environment for consumers to own, manage, and sell access to their digital identity and data through its proprietary BIGtoken platform. An article discussing the company reads, “Through BIGtoken, SRAX has created a symbiotic relationship between big brands desiring to know their consumers better and the consumers themselves who want to remain in control of their data at ever-increasing rates. In exchange for giving brands access to their data by answering surveys, checking into locations, referring friends and more, BIGtoken users are rewarded with points, which they can then redeem for cash and gift cards or make charitable donations. SRAX’s technology then unlocks data to reveal the core consumers of brands across marketing channels. As one of the first companies to offer consumers a significant piece of the data pie, SRAX is building the largest and most valuable opted-in data set in the world.”

To view the full article, visit http://ibn.fm/MSX0w

About SRAX Inc.

SRAX (NASDAQ: SRAX) is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Set to Profit from FDA’s MRTP Pathway Announcement

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, is positioned to benefit from the FDA’s recent announcement that it had authorized the marketing of eight smokeless tobacco products through the modified-risk, tobacco-product (“MRTP”) pathway (http://ibn.fm/3hCAN). An article discussing the company reads, “The FDA approval of the ‘modified risk’ claims was made after reviewing scientific evidence submitted by the manufacturer of the products. The approvals, which are product specific and expire after five years, do not mean the products come with no health risks. Nicotine-based products are addictive and may, according to some studies, induce the onset of cardiovascular, respiratory and gastrointestinal disorders. . . . The patented DehydraTECH(TM) drug-delivery platform mitigates a serious limitation to nicotine ingestion. The human GI system struggles to process nicotine in the forms in which it is presently offered, one reason why there are currently no edible, nicotine, manufactured products available, although some natural foods — eggplant, green pepper, potato, tomato — do contain nicotine. However, DehydraTECH employs a delivery mechanism that improves the bioabsorption and bioavailability of many ingestible substances, as well as their taste and smell, by using lipophilic agents. Application of the technology extends beyond nicotine to nonpsychoactive cannabinoids, vitamins and nonsteroidal anti-inflammatory drugs (NSAIDs).”

To view the full article, visit http://ibn.fm/Bpse8

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Bolsters its Strategic Advisory Board with Kevin Durant’s Thirty Five Ventures

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced the expansion of its strategic advisory board to add Thirty Five Ventures, the business owned by NBA star Kevin Durant and sports business executive Rich Kleiman. According to the update, Thirty Five Ventures will collaborate with Canopy Rivers as it continues to pursue its global growth strategy and strengthen its global portfolio of leading cannabis companies. Canopy Rivers will also look to co-invest with Thirty Five Ventures on cannabis-related deals, leveraging the group’s expertise in brand development and marketing. “We’re thrilled to have Thirty Five Ventures join the Canopy Rivers team,” Narbé Alexandrian, president and CEO of Canopy Rivers, said in the news release. “Kevin Durant and Rich Kleiman have built an incredible brand worldwide, investing in and growing some of the cannabis and tech industry’s hottest companies. We’re excited to combine our venture capital knowledge and cannabis domain expertise, and we believe that this partnership will drive success for our portfolio as we continue to grow it in the years ahead.”

To view the full press release, visit http://ibn.fm/NDs2q

About Canopy Rivers Inc.

Canopy Rivers is a venture capital firm specializing in cannabis. Its unique investment and operating platform is structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its recent receipt of notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”) that indicates Predictive Oncology has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). Per the update, Predictive Oncology received, on November 16, 2018, notification from the Nasdaq (the “Notification Letter on Deficiency”) indicating that the closing bid price per share had been below $1.00 for a period of 30 Consecutive business days and that the Company did not meet the Minimum Price Bid Requirement. The Notification Letter on Deficiency stated that if, at any time during the Compliance Period, the closing bid price per share is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. According to the Notification Letter on Compliance, Nasdaq staff has determined that for 10 consecutive business days, beginning October 29, 2019 through November 11, 2019, the closing bid price of POAI’s common stock has been at $1.00 per share or greater, and the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.

To view the full press release, visit http://ibn.fm/EfINN

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)

Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) CEO to Present at the 12th Annual LD Micro Main Event

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it has been invited to present at the 12th Annual LD Micro Main Event. The event is slated to take place at the Luxe Sunset Boulevard Hotel in Los Angeles, California on December 10-12, 2019. According to the update, Sigma Labs CEO John Rice will host one-on-one meetings throughout the day and is scheduled to present at 3:20 p.m. Pacific Time on Tuesday, December 10, 2019.

To view the full press release, visit http://ibn.fm/V4Pmu

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Expands Canadian Distribution, Initiates Cultivation at Valleyfield Hybrid Greenhouse

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified organic cannabis, today announced receipt of its inaugural purchase order from the BC Liquor Distribution Branch (“BCLDB”), further expanding its Canadian distribution footprint. The company also obtained a Health Canada license amendment, allowing it to launch cultivation operations at its flagship Valleyfield hybrid greenhouse. With the addition of British Columbia, TGOD now has the ability to distribute its products to a total of 527 retail locations across five provinces, or 82% of Canada’s current store count. In 2020, the number of cannabis stores is poised to increase from 639 to over 1,000, and the Company is continuing to strategically develop and nurture solid relationships with provincial boards and retailers, cementing its position as the leading certified organic brand. “TGOD’s high-quality certified organic product and commitment to sustainable cultivation practices resonate with BC consumers. Based on the exceptionally positive feedback we received from our BC medical patients as well as on market research, we believe the province represents an enormous market opportunity for our brand,” TGOD CEO Brian Athaide said in the news release. “As we continue ramping up production, we remain focused on expanding our distribution channels and achieving our goal of distributing nationally in Q1 2020.”

To view the full press release, visit http://ibn.fm/jpA1I

About The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US-OTC: TGODF) is a premium certified organic cannabis company focused on the health and wellness market.  Its certified-organic cannabis is grown in living soil, as nature intended.  The company is committed to cultivating a better tomorrow by producing its products responsibly, with less waste and impact on the environment. Its two Canadian facilities are built to LEED certification standards and its products are sold in recyclable packaging.  In Canada, TGOD plans to expand its product portfolio by launching a series of next-generation cannabis products such as organic teas, infusers and vapes. Through its European subsidiary, HemPoland, the company also distributes premium hemp CBD oil in Europe. By leveraging science and technology, TGOD harnesses the power of nature from seed to sale.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

SRAX Inc. (NASDAQ: SRAX) Reports Promising Q3 Results, Positions Itself for Global Adoption

• SRAX reports Q3 results, shows significant sales increase
• Company continues to make platforms more accessible internationally
• SRAX added partners, including nonprofit associations that give BIGtoken users opportunity to donate earnings to worthy causes

SRAX Inc. (NASDAQ: SRAX) is a digital marketing and data management technology company. Through SRAX’s BIGtoken platform, consumers have the opportunity to both own and monetize their data.

On September 30, 2019, SRAX reported significant Q3 results. On the financial side, the company saw a vertical sales increase of 17% along with a net income of $1.4 million (http://ibn.fm/99oDl). These gains arose out of a critical quarter for the company that included multiple milestones, including a full integration for international users and the first steps in the process of offering BIGtoken in multiple languages.

Christopher Miglino spoke about the traction that the company’s platforms are gaining, noting that “sales from existing platforms grew 11% and 17%, for Q3 2019 compared to Q2 2019 and Q3 2018, respectively, and are already benefiting from advances in BIGtoken.”

Currently a significant backlash is taking place over the privacy of data between consumers and big social media platforms such as Facebook, Twitter, Snapchat and LinkedIn. SRAX is helping consumers take control over their personal data; its BIGtoken website notes that “as a consumer, you are a commodity that generated billions in revenue last year — and none of it went to you” (http://ibn.fm/6AIZ4).

Consumers can use the BIGtoken app to see how much they have earned from marketers. In addition, using the app, consumers have several opportunities to make money from data that is already being taken for free from social media platforms. For instance, BIGtoken platform users can earn points through surveys and location check-ins as well as earn rewards through purchases. Consumers can redeem their points for cash or gift cards, but the app also provides other choices. SRAX has partnered with a number of nonprofits, including the American Heart Association and HealthCorps, to give BIGtoken users the option to donate their earnings to worthy causes.

The BIGtoken app continues to grow in popularity as the company enhances its features. Currently more than 16 million SRAX users exist worldwide, and this number continues to grow. The company recently formed strategic partnerships in India and the Philippines to help increase the number of users.

Based in Los Angeles, SRAX is a digital marketing and data management technology company focused on building the largest and most valuable opted-in data set in the world. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. SRAX delivers a competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html